Business Segments · Development expenses
Pharmaceuticals — Development expenses
Vertex Pharmaceuticals Pharmaceuticals — Development expenses increased by 0.5% to $771.20M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 2.6%, from $791.40M to $771.20M. Over 3 years (FY 2022 to FY 2025), Pharmaceuticals — Development expenses shows an upward trend with a 17.2% CAGR.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2022
Last reportedQ4 2025
How to read this metric
Higher spending indicates active progression of the pipeline, while lower spending may suggest a pause in clinical activity.
Detailed definition
Costs associated with clinical trials, regulatory filings, and the advancement of drug candidates through the developmen...
Peer comparison
Often grouped with research as R&D; peers vary in how they split these specific phases.
Metric ID:
vrtx_segment_pharmaceuticals_development_expensesHistorical Data
16 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $478.40M | $478.40M | $478.40M | $478.40M | $614.33M | $614.33M | $614.33M | $614.33M | $593.00M | $759.30M | $682.10M | $791.40M | $773.60M | $769.10M | $767.70M | $771.20M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +28.4% | +0.0% | +0.0% | +0.0% | -3.5% | +28.0% | -10.2% | +16.0% | -2.2% | -0.6% | -0.2% | +0.5% |
| YoY Change | — | — | — | — | +28.4% | +28.4% | +28.4% | +28.4% | -3.5% | +23.6% | +11.0% | +28.8% | +30.5% | +1.3% | +12.5% | -2.6% |
Range$478.40M – $791.40M
CAGR+13.6%
Avg YoY Growth+17.9%
Median YoY Growth+26.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's pharmaceuticals — development expenses?
- Vertex Pharmaceuticals (VRTX) reported pharmaceuticals — development expenses of $771.20M in Q4 2025.
- How has Vertex Pharmaceuticals's pharmaceuticals — development expenses changed year-over-year?
- Vertex Pharmaceuticals's pharmaceuticals — development expenses decreased by 2.6% year-over-year, from $791.40M to $771.20M.
- What is the long-term trend for Vertex Pharmaceuticals's pharmaceuticals — development expenses?
- Over 3 years (2022 to 2025), Vertex Pharmaceuticals's pharmaceuticals — development expenses has grown at a 17.2% compound annual growth rate (CAGR), from $1.91B to $3.08B.
- What does pharmaceuticals — development expenses mean?
- Spending on clinical trials and the process of getting drugs approved for market.